



adifyline[®]
peptide



PERFECT CURVES AGAINST GRAVITY





PERFECT CURVES AGAINST GRAVITY

- Hexapeptide identified by a combinatorial chemistry approach from a library of 49,521,980 hexapeptides.
- Screened using the reporter gene assay in a transfected cell line where luciferase expression was controlled by PGC-1 α promoter activity.




adifyline®
peptide

- ✓ Enhances adipocyte maturation by boosting PGC-1 α expression.
- ✓ Induces a higher lipid accumulation.
- ✓ Increases local volume (cheeks and breasts) by growing adipose tissue volume.



1. Effect on PGC-1 α expression




ADIFYLINE® peptide promoted PGC-1 α expression by more than 61%



- Human preadipocytes were incubated for 24 h in a growth medium and differentiated with preadipocyte differentiation medium (PDM-2) in the presence of ADIFYLINE® peptide.
- After 10 days, cells were lysed, RNA was extracted and reverse transcription was performed. The resulting cDNA was analyzed by quantitative RT-PCR.



2. Effect on lipid accumulation



- ADIFYLINE® *peptide* was added to human preadipocytes during their differentiation in the PDM-2.
- After 10 days, AdipoRed™ reagent was added to observe fluorescence, which was measured and converted into lipid levels.

Lipid accumulation is higher in cells treated with ADIFYLINE® *peptide*





1. Facial volume increase

- 22 female volunteers (aged between 50 and 60).
- Application of a cream containing 2% ADIFYLINE® *peptide solution* on the cheeks twice a day for 14 days.
- Cheek volume was measured at the end of the study.



Cheek volume was analyzed by Fringe Projection. This technique allows the direct acquisition of the morphology of the studied area in 3D, being able to obtain volume in mm³.



Cheek volume increased by 12% after 14 days with ADIFYLINE® *peptide*





2. Breast volume increase

- 22 female volunteers (aged 25 to 40) with a 80-90 European bra cup size.
- Application of a cream containing 2% ADIFYLINE® *peptide solution* on a breast and the placebo on the other, twice a day for 56 days.
- Breast volume was measured at day 14, 28 and 56.



• FOITS technique was used to measure breast volume.



ADIFYLINE® *peptide* improved breast volume by 30-fold compared to placebo after 56 days



COSMETIC BENEFITS

Perfect curves
against gravity

adifyline®
peptide

Stimulates adipogenesis
for an attractive
appearance

Promotes PGC-1 α expression,
a novel approach

Higher lipid
accumulation in
the desired areas

Increases
cheek
volume

In only 14 days

Provides a
curvy
silhouette

Enhancing
breast volume



adifyline[®]
peptide



PERFECT CURVES AGAINST GRAVITY

ADIFYLINE[®] and AIMTEC[®] are owned by The Lubrizol Corporation.

The other tradenames and trademarks used herein belong to their respective and lawful owners.

Note: Graphs and photographs of efficacy tests are available for customer use provided that the final product contains the same concentration of active as the formulations in our tests. Customers must request written permission for use of the graphic material and/or ingredient tradenames to Lipotec. Customers are responsible for compliance with local and international advertising regulations.

The specific situation of the trademark in each country may vary and we recommend that you contact us for updated information.

Disclaimer:

While the claims and supporting data provided in this publication are believed to be reliable and they are presented free and for guidance only, there are no warranties of any kind made as to its accuracy, suitability for particular applications, how the product(s) will perform in combination with other substance or in the user's process or the results obtained. All expressed and implied warranties are disclaimed. Lipotec MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. The recipient is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulations and assumes all risk and liability of any use or handling of any materials. Recipient of this publication agrees to indemnify and hold harmless each entity of the LIPOTEC organization for any and all actions arising from recipient's use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and not present this publication as evidence of finished product claim substantiation to any regulatory authority. Nothing contained herein is to be considered as permission, recommendation, nor as an inducement to practice any patented invention without permission of the patent owner.

